P26.02 A Phase II Trial of Neoadjuvant Osimertinib for Surgically Resectable EGFR-Mutant Non-Small Cell Lung Cancer: Updated Results
C. Blakely(University of California, San Francisco), David M. Jablons(City College of San Francisco), Julia Rotow(University of California, San Francisco), Tejas Patil(Sidney Kimmel Comprehensive Cancer Center), Anatoly Urisman(City College of San Francisco), Robert C. Doebele(Aurora University), Bianca Bacaltos(University of California, San Francisco), Dara L. Aisner(University of Colorado System), Wen‐Shuo Wu(University of San Francisco), Johannes R. Kratz(University of California, San Francisco), Matthew A. Gubens(University of California, San Francisco), Kirk D. Jones, Erin L. Schenk(University of Colorado Anschutz Medical Campus), Jonathan W. Riess(University of California Davis Medical Center), D. Lucas Kerr(UCSF Helen Diller Family Comprehensive Cancer Center), Sun Hyung Joo(St George's, University of London), Trever G. Bivona(University of California, San Francisco)
Cited by 7
Related Papers
Association of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
|Neurology|1993|3.8k
Oncogenic Signaling Pathways in The Cancer Genome Atlas
|Cell|2018|3.4k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k